Former FDA Commissioner Dr. Robert Califf said transparency is essential as federal officials investigate a multi-state cyclospora outbreak on Monday.
The call for openness comes as the agency struggles to pinpoint the exact source of the parasite, which has affected thousands of people across the U.S. [1]. Because foodborne outbreaks can spread rapidly through global supply chains, delays in identifying the contamination point can lead to more infections and prolonged public health risks.
Speaking on CNBC’s The Exchange, Califf said he emphasized the need for clear communication between regulators and the public. "We need as much transparency as we can get," Califf said.
The FDA continues to investigate the origin of the outbreak. An FDA spokesperson said the agency still believes the parasite originated at Taylor Farms in Mexico [2]. This suspicion persists despite complications in the testing process.
Recent reports indicate the investigation has faced setbacks. Lucia Auerbach said the agency admits a sample was a false positive, but the epidemiological investigation continues [3]. This contradiction highlights the difficulty of tracing cyclospora, which often requires precise timing and sampling to confirm a source.
The FDA has not apologized for the initial sample error, though it maintains that the broader evidence still points toward the Mexican supplier [2]. The agency is working to determine how the parasite entered the food supply, and whether other facilities are at risk.
Public health officials are monitoring the situation to prevent further cases. The focus remains on whether the contamination was a localized event or a systemic failure in produce safety protocols at the suspected facility.
“"We need as much transparency as we can get."”
The tension between the FDA's continued suspicion of Taylor Farms and the admission of a false-positive sample suggests a high level of uncertainty in the forensic side of the investigation. When epidemiological data—the patterns of who got sick and what they ate—conflicts with laboratory results, the agency must rely on transparency to maintain public trust while avoiding premature accusations against international suppliers.
